During the last session, Pliant Therapeutics Inc (NASDAQ:PLRX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $10.92, reflecting an intraday loss of -1.97% or -$0.22. The 52-week high for the PLRX share is $18.92, that puts it down -73.26 from that peak though still a striking 6.41% gain since the share price plummeted to a 52-week low of $10.22. The company’s market capitalization is $664.52M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 513.67K shares over the past three months.
Pliant Therapeutics Inc (PLRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PLRX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
Pliant Therapeutics Inc (NASDAQ:PLRX) trade information
Pliant Therapeutics Inc (PLRX) registered a -1.97% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.97% in intraday trading to $10.92, hitting a weekly high. The stock’s 5-day price performance is -5.86%, and it has moved by -17.34% in 30 days. Based on these gigs, the overall price performance for the year is -37.39%. The short interest in Pliant Therapeutics Inc (NASDAQ:PLRX) is 7.17 million shares and it means that shorts have 11.92 day(s) to cover.
The consensus price target of analysts on Wall Street is $35.5, which implies an increase of 69.24% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $33 and $38 respectively. As a result, PLRX is trading at a discount of -247.99% off the target high and -202.2% off the low.
Pliant Therapeutics Inc (PLRX) estimates and forecasts
Statistics show that Pliant Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Pliant Therapeutics Inc (PLRX) shares have gone down -13.95% during the last six months, with a year-to-date growth rate less than the industry average at -32.73% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -22.68%. While earnings are projected to return -32.31% in 2025, the next five years will return -13.88% per annum.
PLRX Dividends
Pliant Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Pliant Therapeutics Inc (NASDAQ:PLRX)’s Major holders
Pliant Therapeutics Inc insiders own 2.91% of total outstanding shares while institutional holders control 111.75%, with the float percentage being 115.10%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 232.0 institutions own stock in it. As of 2024-06-30, the company held over 5.97 million shares (or 9.9238% of all shares), a total value of $64.2 million in shares.
The next largest institutional holding, with 4.97 million shares, is of BLACKROCK INC.’s that is approximately 8.2612% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $53.45 million.
Also, the Mutual Funds coming in first place with the largest holdings of Pliant Therapeutics Inc (PLRX) shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 2.41 shares. This amounts to just over 3.97 percent of the company’s overall shares, with a $26.37 million market value. The same data shows that the other fund manager holds slightly less at 2.03, or about 3.34% of the stock, which is worth about $22.17 million.
